RT Journal Article
SR Electronic
T1 Neutrophil extracellular traps and thrombosis in COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.30.20086736
DO 10.1101/2020.04.30.20086736
A1 Yu Zuo
A1 Melanie Zuo
A1 Srilakshmi Yalavarthi
A1 Kelsey Gockman
A1 Jacqueline A. Madison
A1 Hui Shi
A1 Jason S. Knight
A1 Yogendra Kanthi
YR 2020
UL http://medrxiv.org/content/early/2020/05/05/2020.04.30.20086736.abstract
AB Here, we report on four patients whose hospitalizations for COVID-19 were complicated by venous thromboembolism (VTE). All demonstrated high levels of D-dimer as well as high neutrophil-to-lymphocyte ratios. For three patients, we were able to test sera for neutrophil extracellular trap (NET) remnants and found significantly elevated levels of cell-free DNA, myeloperoxidase-DNA complexes, and citrullinated histone H3. Neutrophil-derived S100A8/A9 (calprotectin) was also elevated. Given strong links between hyperactive neutrophils, NET release, and thrombosis in many inflammatory diseases, the potential relationship between NETs and VTE should be further investigated in COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work was supported by a COVID-19 Cardiovascular Impact Research Ignitor Grant from the Michigan Medicine Frankel Cardiovascular Center as well as by the A. Alfred Taubman Medical Research Institute.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOnce published in a peer-reviewed journal, all primary data will be available upon request to the corresponding authors.